Pharma Focus Asia

Simtra BioPharma Solutions Invests US$250 million to Construct New Manufactuting Site in Indiana, USA


Simtra BioPharma Solutions invests US$250 million to construct new sterile fill/finish manufacturing site in Indiana, USA.


A new, state of the art 150,000 square foot building is designed to accommodate two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line boasting three 30 square metre lyophilisers. Each process suite within the new structure will feature dedicated formulation and compounding rooms.

Additionally, the expansion project will introduce a specialised clinical line tailored to bolster development and clinical operations. This line will make efficient use of the existing facility infrastructure. 

This will enable the Bloomington campus to more effectively handle projects in the early stages of development (Phase I or II) and keep projects onsite to scale up towards commercialisation.

Construction of the new facility is slated to commence in June 2024 and is expected to span a two-year period, with GMP compliance targeted for late 2026.

The new campus is projected to generate hundreds of job opportunities in Bloomington.


Name        Simtra BioPharma Solutions
Type          New Construction
Budget     US$250 million
Year           2026

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference